These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 18698032)

  • 21. Tumor resensitization to erlotinib following brief substitution of cetuximab.
    Epstein RJ; Leung TW
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1111-2. PubMed ID: 18283460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma.
    Pipas JM; Zaki BI; McGowan MM; Tsapakos MJ; Ripple GH; Suriawinata AA; Tsongalis GJ; Colacchio TA; Gordon SR; Sutton JE; Srivastava A; Smith KD; Gardner TB; Korc M; Davis TH; Preis M; Tarczewski SM; MacKenzie TA; Barth RJ
    Ann Oncol; 2012 Nov; 23(11):2820-2827. PubMed ID: 22571859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
    Ali S; Banerjee S; Schaffert JM; El-Rayes BF; Philip PA; Sarkar FH
    J Cell Biochem; 2010 May; 110(1):171-81. PubMed ID: 20213764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
    Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
    Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Her signaling in pancreatic cancer.
    Burtness B
    Expert Opin Biol Ther; 2007 Jun; 7(6):823-9. PubMed ID: 17555368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.
    Kadera BE; Toste PA; Wu N; Li L; Nguyen AH; Dawson DW; Donahue TR
    Clin Cancer Res; 2015 Jan; 21(1):157-65. PubMed ID: 25348515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
    Burris H; Rocha-Lima C
    Oncologist; 2008 Mar; 13(3):289-98. PubMed ID: 18378539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving treatment of pancreatic cancer.
    Philip PA
    Lancet Oncol; 2008 Jan; 9(1):7-8. PubMed ID: 18177814
    [No Abstract]   [Full Text] [Related]  

  • 30. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
    Wang M; Zhao J; Zhang LM; Li H; Yu JP; Ren XB; Wang CL
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2069-77. PubMed ID: 22821179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB.
    El-Rayes BF; Ali S; Ali IF; Philip PA; Abbruzzese J; Sarkar FH
    Cancer Res; 2006 Nov; 66(21):10553-9. PubMed ID: 17079479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
    Leeman-Neill RJ; Cai Q; Joyce SC; Thomas SM; Bhola NE; Neill DB; Arbiser JL; Grandis JR
    Clin Cancer Res; 2010 May; 16(9):2571-9. PubMed ID: 20388852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
    Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
    Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.
    Yokoi K; Sasaki T; Bucana CD; Fan D; Baker CH; Kitadai Y; Kuwai T; Abbruzzese JL; Fidler IJ
    Cancer Res; 2005 Nov; 65(22):10371-80. PubMed ID: 16288027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody.
    Huang ZQ; Buchsbaum DJ; Raisch KP; Bonner JA; Bland KI; Vickers SM
    J Surg Res; 2003 May; 111(2):274-83. PubMed ID: 12850474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
    Ng SS; Tsao MS; Nicklee T; Hedley DW
    Mol Cancer Ther; 2002 Aug; 1(10):777-83. PubMed ID: 12492110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
    Zhang X; Zhang H; Tighiouart M; Lee JE; Shin HJ; Khuri FR; Yang CS; Chen Z'; Shin DM
    Int J Cancer; 2008 Sep; 123(5):1005-14. PubMed ID: 18546267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
    Duffy A; Kortmansky J; Schwartz GK; Capanu M; Puleio S; Minsky B; Saltz L; Kelsen DP; O'Reilly EM
    Ann Oncol; 2008 Jan; 19(1):86-91. PubMed ID: 17878176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model.
    Bozec A; Sudaka A; Fischel JL; Brunstein MC; Etienne-Grimaldi MC; Milano G
    Br J Cancer; 2008 Jul; 99(1):93-9. PubMed ID: 18577994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
    Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.